在美国,心衰(HF)为每年住院的前位病因,尤其是充血性HF,且充血性HF往往伴有液体潴留与低钠血症,而口服非肽类选择性加压素V2受体拮抗剂Tolvaptan却能改善液体潴留及低钠血症。本文旨在就Tolvaptan辅助常规治疗对充血性HF住院患者的近期药效及其安全性等进行了大样本分析。对象 In the United States, heart failure (HF) is the leading cause of annual hospitalizations, especially congestive HF, and congestive HF is often associated with fluid retention and hyponatremia, whereas oral non-peptide selective vasopressin V2 receptor Antagonist Tolvaptan can improve fluid retention and hyponatremia. This article aims to conduct a large sample analysis of the short-term efficacy and safety of Tolvaptan-assisted routine therapies for patients with congestive HF. Object